

# François Moreau-Gaudry

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8049191/publications.pdf>

Version: 2024-02-01

20  
papers

888  
citations

516215

16  
h-index

794141

19  
g-index

20  
all docs

20  
docs citations

20  
times ranked

1399  
citing authors

#	ARTICLE	IF	CITATIONS
1	CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations. <i>Nature Communications</i> , 2019, 10, 1136.	5.8	292
2	High Clinical Value of Liquid Biopsy to Detect Circulating Tumor Cells and Tumor Exosomes in Pancreatic Ductal Adenocarcinoma Patients Eligible for Up-Front Surgery. <i>Cancers</i> , 2019, 11, 1656.	1.7	79
3	Circulating Tumor Cell Clusters: United We Stand Divided We Fall. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2653.	1.8	73
4	CD63-GPC1-Positive Exosomes Coupled with CA19-9 Offer Good Diagnostic Potential for Resectable Pancreatic Ductal Adenocarcinoma. <i>Translational Oncology</i> , 2019, 12, 1395-1403.	1.7	58
5	Preventing Pluripotent Cell Teratoma in Regenerative Medicine Applied to Hematology Disorders. <i>Stem Cells Translational Medicine</i> , 2017, 6, 382-393.	1.6	53
6	Effective Gene Therapy of Mice with Congenital Erythropoietic Porphyria Is Facilitated by a Survival Advantage of Corrected Erythroid Cells. <i>American Journal of Human Genetics</i> , 2008, 82, 113-124.	2.6	44
7	CRISPR-Cas9 globin editing can induce megabase-scale copy-neutral losses of heterozygosity in hematopoietic cells. <i>Nature Communications</i> , 2021, 12, 4922.	5.8	44
8	FGFR3 has tumor suppressor properties in cells with epithelial phenotype. <i>Molecular Cancer</i> , 2013, 12, 83.	7.9	37
9	Next-Generation Cancer Biomarkers: Extracellular Vesicle DNA as a Circulating Surrogate of Tumor DNA. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 622048.	1.8	29
10	Tumor-proximal liquid biopsy to improve diagnostic and prognostic performances of circulating tumor cells. <i>Molecular Oncology</i> , 2019, 13, 1811-1826.	2.1	27
11	ON-Target Adverse Events of CRISPR-Cas9 Nuclease: More Chaotic than Expected. <i>CRISPR Journal</i> , 2022, 5, 19-30.	1.4	27
12	Congenital erythropoietic porphyria: mutation update and correlations between genotype and phenotype. <i>Cellular and Molecular Biology</i> , 2009, 55, 53-60.	0.3	25
13	Erythropoietic Porphyrias: Animal Models and Update in Gene-Based Therapies. <i>Current Gene Therapy</i> , 2008, 8, 176-186.	0.9	24
14	Metabolic Correction of Congenital Erythropoietic Porphyria with iPSCs Free of Reprogramming Factors. <i>American Journal of Human Genetics</i> , 2012, 91, 109-121.	2.6	19
15	In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens. <i>Molecular Cancer</i> , 2012, 11, 81.	7.9	19
16	Generation of induced pluripotent stem cells-derived hepatocyte-like cells for ex vivo gene therapy of primary hyperoxaluria type 1. <i>Stem Cell Research</i> , 2019, 38, 101467.	0.3	19
17	Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells. <i>Leukemia</i> , 2017, 31, 65-74.	3.3	11
18	Mutation-Specific Guide RNA for Compound Heterozygous Porphyria On-target Scarless Correction by CRISPR/Cas9 in Stem Cells. <i>Stem Cell Reports</i> , 2020, 15, 677-693.	2.3	6

#	ARTICLE	IF	CITATIONS
19	Spleen route accelerates engraftment of human hematopoietic stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2021, 569, 23-28.	1.0	2
20	Recent progress in genome editing for gene therapy applications: the French perspective. <i>Human Gene Therapy</i> , 2021, 32, 1059-1075.	1.4	0